Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
5 raisons identifiées
Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (2 thèses dirigées)
Référence presse grand public
Cité 2 fois dans les médias — pédagogie reconnue
Expérience confirmée
19 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
120.1 rhumatos / 100 000 hab. — département bien doté
19ans d'exercice (thèse 2007)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Broncho-pneumopathie chronique obstructive secondaire à l’exposition aux poussières organiques : caractérisation pulmonaire et systémique.
2019Doctorant·e : Thibaud Soumagne
Epidémiologie et évaluation quantitative du risque de broncho-pneumopathie chronique obstructive en milieu agricole
2018Doctorant·e : Alicia Guillien
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Prognostic factors in interstitial lung disease-associated pulmonary hypertension: data from the HYPID cohort and the French Pulmonary Hypertension Registry
2026ArticleEuropean Respiratory Journal
Organ distribution bias in chest computed tomography scans: a methodological pitfall for visceral adipose tissue measurement
2026ArticleClinical Nutrition
Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis
2026ArticleRespiratory Medicine and Research
Pectoral muscle area derived from chest computed tomography to identify quadriceps muscle weakness in COPD
2025ArticleERJ Open Research
Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities
2025ArticleEuropean Respiratory Journal
The Favorable impact of everolimus on Chronic lung allograft dysfunction in lung transplant recipients
2024ArticleInternational Immunopharmacology
Different pathways to lung cancer diagnosis in a real-life setting
2024ArticleRespiratory Medicine and Research
Real world evidence in asthma: what to expect beyond randomised controlled trials?
2024ArticleEuropean Respiratory Journal
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL NORD - CHU38
BD DE LA CHANTOURNE, 38700 LA TRONCHE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Le Dauphiné Libéré · 14/10/2019
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOZW5OLUZ1cUgwZmhLckhLZ0J1Q01qQm5CcnVaNURKTWZkcEFWRUp3WkdTYkk5SUt6Tzd2UktpOGdIaW5aN2RyY1oxMjBHbkpxcnY2anZuUllPWVFtYnd3bUZOOEFxUjZFRzVHNDdXdTRJMVh2dTdMdjlMQlVwNDlaYTFPZG5pVVp0X1h0dnhn?oc=5" target="_blank">grenoble (isère). Une première fran
📰 Le Dauphiné Libéré · 11/10/2019
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQb3pjRzVDZkx4aEY1dWNtT0JrSEpNRnJrRnJ2MUUyWEVlcjVoMUhVa2lnU0EzdVV5Q1Z4QjMwS2ZaWTRfZWhzUmdEc3JreXdiQXdCWmhTRXlRNmlEVlhJNWlDbWliRU5GSEQ2cGlTR3VzbnZSVGpmWWpDQTN1S0hiNjNWX3pCbWZjZXh5dVdKTV9hWDJ4LVlISDlqdzJvQjVBMDZ4SWdsSTZZd0VSLU0yb0xvTDBVQTRQdm
American journal of respiratory and critical care medicine · 2021
Abstract Rationale The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. Methods A retrospective analysis of incident patients with idiopathic, heritable, or anorexigen-induced PAH enrolled in the French Pulmonary Hypertension Registry (January 2006 to December 2018) was conducted. Survival was assessed according to the initial strategy: monotherapy, dual therapy, or triple-combination therapy (two oral medications and a parenteral prostacyclin). Measurements and Main Results Among 1,611 enrolled patients, 984 were initiated on monotherapy, 551 were initiated on dual therapy, and 76 were initiated on triple therapy. The triple-combination group was younger and had fewer comorbidities but had a higher mortality risk. The survival rate was higher with the use of triple therapy (91% at 5 yr) as compared with dual therapy or monotherapy (both 61% at 5 yr) (P &lt; 0.001). Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual therapy (10-yr survival, 85% vs. 65%). In high-risk patients (n = 243), the survival rate was higher with triple therapy than with monotherapy or dual therapy, whereas there was no difference between monotherapy and double therapy. In intermediate-risk patients (n = 1,134), survival improved with an increasing number of therapies. In multivariable Cox regression, triple therapy was independently associated with a lower risk of death (hazard ratio, 0.29; 95% confidence interval, 0.11–0.80; P = 0.017). Among the 148 patients initiated on a parenteral prostacyclin, those on triple therapy had a higher survival rate than those on monotherapy or dual therapy. Conclusions Initial triple-combination therapy that includes parenteral prostacyclin seems to be associated with a higher survival rate in PAH, particularly in the youngest high-risk patients.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2021
Frontiers in cardiovascular medicine · 2022
BackgroundTrastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is a safe and effective supportive therapy in the management of side effects, but the cardioprotective effects of exercise are still unclear.ObjectivesThe primary aim of this study was to test whether trastuzumab-induced cardiotoxicity [left ventricular ejection fraction (LVEF) under 50%, or an absolute drop in LVEF of 10%] was reduced after a supervised exercise program of 3 months in patients with HER2-positive breast cancer. Secondary endpoints were to evaluate (i) cardiotoxicity rates using other criteria, (ii) cardiac parameters, (iii) cardiorespiratory fitness and (iv) whether a change in LVEF influences the cardiorespiratory fitness.Methods89 women were randomized to receive adjuvant trastuzumab in combination with a training program (training group: TG; n = 46) or trastuzumab alone (control group: CG; n = 43). The primary and secondary endpoints were evaluated at the end of the supervised exercise program of 3 months (T3).ResultsAfter exercise program, 90.5 % of TG patients and 81.8% of CG patients did not exhibit cardiotoxicity. Furthermore, whatever the used criterion, percentage of patients without cardiotoxicity were greater in TG (97.6 and 100% respectively) than in CG (90.9 and 93.9% respectively). LVEF and GLS values remained stable in both groups without any difference between the groups. In contrast, at T3, peak VO2 (+2.6 mL.min−1.kg−1; 95%CI, 1.8 to 3.4) and maximal power (+21.3 W; 95%CI, 17.3 to 25.3) increased significantly in TG, whereas they were unchanged in CG (peak VO2: +0.2 mL.min−1.kg−1; 95%CI, −0.5 to 0.9 and maximal power: +0.7 W, 95%CI, −3.6 to 5.1) compared to values measured at T0. No correlation between LVEF changes and peak VO2 or maximal power was observed.ConclusionA 12-week supervised exercise regimen was safe and improved the cardiopulmonary fitness in particular peak VO2, in HER2-positive BC patients treated with adjuvant trastuzumab therapy. The study is under powered to come to any conclusion regarding the effect on cardiotoxicity.Clinical trial registrationwww.ClinicalTrials.gov, identifier: NCT02433067.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Rheumatology (Oxford, England) · 2025 · Journal Article
Razat L, Simon M, Quétant S, Degano B
Respiratory medicine · 2025 · Journal Article
Piliero N, Salvat M, Bertoletti L, Bouvaist H, et al.
Respiratory medicine and research · 2024 · Journal Article
Raëth J, Malbert C, Pinsolle J, Arbib F, et al.
Respiratory medicine and research · 2023 · Journal Article
Soumagne T, Quétant S, Guillien A, Falque L, et al.
Journal of cardiopulmonary rehabilitation and prevention · 2023 · Journal Article
Barret T, Degano B, Bouvaist H, Pison C, et al.
Respiratory medicine and research · 2023 · Journal Article
Pernot J, Ribon A, Degano B
Respiratory medicine and research · 2022 · Randomized Controlled Trial
Elhage S, Laurent L, Diallo K, Bouhaddi M, et al.
Transplant immunology · 2022 · Journal Article
Liaigre L, Perrier Q, Orhon P, Briault A, et al.
Frontiers in cardiovascular medicine · 2022 · Journal Article
Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, et al.
Respiratory medicine and research · 2022 · Practice Guideline
Zysman M, Baptista BR, Soumagne T, da Silva VM, et al.
Life (Basel, Switzerland) · 2022 · Journal Article
Pépin JL, Degano B, Tamisier R, Viglino D
Respiratory medicine · 2021 · Journal Article
Hartman JE, Conway F, Degano B, Augustijn SWS, et al.
American journal of respiratory and critical care medicine · 2021 · Evaluation Study
Boucly A, Savale L, Jaïs X, Bauer F, et al.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2021 · Journal Article
Dauriat G, Reynaud-Gaubert M, Cottin V, Lamia B, et al.
Environmental research · 2020 · Journal Article
Soumagne T, Degano B, Guillien A, Annesi-Maesano I, et al.
International journal of chronic obstructive pulmonary disease · 2020 · Journal Article
Soumagne T, Guillien A, Roche N, Annesi-Maesano I, et al.
Respiratory medicine and research · 2026 · Journal Article
Cottin V, Crestani B, Planès C, Chambellan A, et al.
American journal of respiratory and critical care medicine · 2025 · Journal Article
Shah PL, Slebos DJ, Sue R, Bhatt SP, et al.
The European respiratory journal · 2024 · Editorial
Soumagne T, Degano B
The European respiratory journal · 2026 · Journal Article
Diesler R, Turquier S, Reynaud-Gaubert M, Lestelle F, et al.
JAMA network open · 2022 · Journal Article
Boussat B, Cazzorla F, Le Marechal M, Pavese P, et al.
Respiratory research · 2021 · Published Erratum
Pison C, Shah PL, Slebos DJ, Ninane V, et al.
Respiratory research · 2021 · Journal Article
Pison C, Shah PL, Slebos DJ, Ninane V, et al.
Transplant immunology · 2025 · Case Reports
Mallet H, Razat L, Perrier Q, Briault A, et al.
The European respiratory journal · 2024 · Editorial
Soumagne T, Degano B
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023 · Journal Article
Cascarano E, Frappa M, Degano B, Pelloux I, et al.
Respiration; international review of thoracic diseases · 2021 · Comparative Study
Fedi A, Keddache S, Quétant S, Guillien A, et al.
La Revue de medecine interne · 2025 · Journal Article
Petit P, Faure D, Quetant S, Degano B, et al.
Is atopy a risk indicator of chronic obstructive pulmonary disease in dairy farmers?
Abstract Allergic mechanisms related to environmental and occupational exposure have been suggested to contribute to the development of chronic obstructive pulmonary disease (COPD). Objectives To investigate the relation
Gender differences in respiratory health outcomes among farming cohorts around the globe: findings from the AGRICOH consortium
<b>Purpose</b>: Respiratory hazards of farming have been identified for centuries, with little focus on gender differences. We used data from the AGRICOH consortium, a collective of prospective cohorts of agricultural wo
Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3)
Abstract Background Targeted lung denervation (TLD) is a bronchoscopically delivered ablation therapy that selectively interrupts pulmonary parasympathetic nerve signaling. The procedure has the potential to alter airway
Is atopy a risk indicator of chronic obstructive pulmonary disease in dairy farmers?
Abstract Allergic mechanisms related to environmental and occupational exposure have been suggested to contribute to the development of chronic obstructive pulmonary disease (COPD). Objectives To investigate the relation
Gender differences in respiratory health outcomes among farming cohorts around the globe: findings from the AGRICOH consortium
<b>Purpose</b>: Respiratory hazards of farming have been identified for centuries, with little focus on gender differences. We used data from the AGRICOH consortium, a collective of prospective cohorts of agricultural wo
Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3)
Abstract Background Targeted lung denervation (TLD) is a bronchoscopically delivered ablation therapy that selectively interrupts pulmonary parasympathetic nerve signaling. The procedure has the potential to alter airway
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).